Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Planning to improve global health: the next decade of tuberculosis control</title>
<author><name sortKey="Maher, Dermot" sort="Maher, Dermot" uniqKey="Maher D" first="Dermot" last="Maher">Dermot Maher</name>
<affiliation><nlm:aff id="aff1"><addr-line>Stop TB Department</addr-line>
,<institution>WHO</institution>
,<addr-line>Geneva</addr-line>
,<country>Switzerland</country>
.</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Dye, Chris" sort="Dye, Chris" uniqKey="Dye C" first="Chris" last="Dye">Chris Dye</name>
<affiliation><nlm:aff id="aff1"><addr-line>Stop TB Department</addr-line>
,<institution>WHO</institution>
,<addr-line>Geneva</addr-line>
,<country>Switzerland</country>
.</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Floyd, Katherine" sort="Floyd, Katherine" uniqKey="Floyd K" first="Katherine" last="Floyd">Katherine Floyd</name>
<affiliation><nlm:aff id="aff1"><addr-line>Stop TB Department</addr-line>
,<institution>WHO</institution>
,<addr-line>Geneva</addr-line>
,<country>Switzerland</country>
.</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Pantoja, Andrea" sort="Pantoja, Andrea" uniqKey="Pantoja A" first="Andrea" last="Pantoja">Andrea Pantoja</name>
<affiliation><nlm:aff id="aff1"><addr-line>Stop TB Department</addr-line>
,<institution>WHO</institution>
,<addr-line>Geneva</addr-line>
,<country>Switzerland</country>
.</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Lonnroth, Knut" sort="Lonnroth, Knut" uniqKey="Lonnroth K" first="Knut" last="Lonnroth">Knut Lonnroth</name>
<affiliation><nlm:aff id="aff1"><addr-line>Stop TB Department</addr-line>
,<institution>WHO</institution>
,<addr-line>Geneva</addr-line>
,<country>Switzerland</country>
.</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Reid, Alasdair" sort="Reid, Alasdair" uniqKey="Reid A" first="Alasdair" last="Reid">Alasdair Reid</name>
<affiliation><nlm:aff id="aff1"><addr-line>Stop TB Department</addr-line>
,<institution>WHO</institution>
,<addr-line>Geneva</addr-line>
,<country>Switzerland</country>
.</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Nathanson, Eva" sort="Nathanson, Eva" uniqKey="Nathanson E" first="Eva" last="Nathanson">Eva Nathanson</name>
<affiliation><nlm:aff id="aff1"><addr-line>Stop TB Department</addr-line>
,<institution>WHO</institution>
,<addr-line>Geneva</addr-line>
,<country>Switzerland</country>
.</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Pennas, Thad" sort="Pennas, Thad" uniqKey="Pennas T" first="Thad" last="Pennas">Thad Pennas</name>
<affiliation><nlm:aff id="aff1"><addr-line>Stop TB Department</addr-line>
,<institution>WHO</institution>
,<addr-line>Geneva</addr-line>
,<country>Switzerland</country>
.</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Fruth, Uli" sort="Fruth, Uli" uniqKey="Fruth U" first="Uli" last="Fruth">Uli Fruth</name>
<affiliation><nlm:aff id="aff2"><addr-line>Department of Immunization</addr-line>
,<addr-line>Vaccines and Biologicals</addr-line>
,<institution>WHO</institution>
,<addr-line>Geneva</addr-line>
,<country>Switzerland</country>
.</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Cunningham, Jane" sort="Cunningham, Jane" uniqKey="Cunningham J" first="Jane" last="Cunningham">Jane Cunningham</name>
<affiliation><nlm:aff id="aff3"><addr-line>Special Programme for Research and Training in Tropical Diseases</addr-line>
,<institution>WHO</institution>
,<addr-line>Geneva</addr-line>
,<country>Switzerland</country>
.</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Ignatius, Heather" sort="Ignatius, Heather" uniqKey="Ignatius H" first="Heather" last="Ignatius">Heather Ignatius</name>
<affiliation><nlm:aff id="aff4"><addr-line>Working Group on New Drugs</addr-line>
,<addr-line>Stop TB Partnership</addr-line>
,<addr-line>New York</addr-line>
,<addr-line>NY</addr-line>
,<country>USA</country>
.</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Raviglione, Mario C" sort="Raviglione, Mario C" uniqKey="Raviglione M" first="Mario C" last="Raviglione">Mario C. Raviglione</name>
<affiliation><nlm:aff id="aff1"><addr-line>Stop TB Department</addr-line>
,<institution>WHO</institution>
,<addr-line>Geneva</addr-line>
,<country>Switzerland</country>
.</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Koek, Irene" sort="Koek, Irene" uniqKey="Koek I" first="Irene" last="Koek">Irene Koek</name>
<affiliation><nlm:aff id="aff5"><addr-line>Infectious Diseases Division</addr-line>
,<addr-line>Bureau for Global Health</addr-line>
,<addr-line>US Agency for International Development</addr-line>
,<addr-line>1300</addr-line>
Pennsylvania Ave., Washington, DC 20523, USA.</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Espinal, Marcos" sort="Espinal, Marcos" uniqKey="Espinal M" first="Marcos" last="Espinal">Marcos Espinal</name>
<affiliation><nlm:aff id="aff6"><addr-line>Stop TB Partnership Secretariat</addr-line>
,<institution>WHO</institution>
,<addr-line>Geneva</addr-line>
,<country>Switzerland</country>
.</nlm:aff>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">17639217</idno>
<idno type="pmc">2636650</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2636650</idno>
<idno type="RBID">PMC:2636650</idno>
<idno type="doi">10.2471/06.037820</idno>
<date when="2007">2007</date>
<idno type="wicri:Area/Pmc/Corpus">000E71</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000E71</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Planning to improve global health: the next decade of tuberculosis control</title>
<author><name sortKey="Maher, Dermot" sort="Maher, Dermot" uniqKey="Maher D" first="Dermot" last="Maher">Dermot Maher</name>
<affiliation><nlm:aff id="aff1"><addr-line>Stop TB Department</addr-line>
,<institution>WHO</institution>
,<addr-line>Geneva</addr-line>
,<country>Switzerland</country>
.</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Dye, Chris" sort="Dye, Chris" uniqKey="Dye C" first="Chris" last="Dye">Chris Dye</name>
<affiliation><nlm:aff id="aff1"><addr-line>Stop TB Department</addr-line>
,<institution>WHO</institution>
,<addr-line>Geneva</addr-line>
,<country>Switzerland</country>
.</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Floyd, Katherine" sort="Floyd, Katherine" uniqKey="Floyd K" first="Katherine" last="Floyd">Katherine Floyd</name>
<affiliation><nlm:aff id="aff1"><addr-line>Stop TB Department</addr-line>
,<institution>WHO</institution>
,<addr-line>Geneva</addr-line>
,<country>Switzerland</country>
.</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Pantoja, Andrea" sort="Pantoja, Andrea" uniqKey="Pantoja A" first="Andrea" last="Pantoja">Andrea Pantoja</name>
<affiliation><nlm:aff id="aff1"><addr-line>Stop TB Department</addr-line>
,<institution>WHO</institution>
,<addr-line>Geneva</addr-line>
,<country>Switzerland</country>
.</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Lonnroth, Knut" sort="Lonnroth, Knut" uniqKey="Lonnroth K" first="Knut" last="Lonnroth">Knut Lonnroth</name>
<affiliation><nlm:aff id="aff1"><addr-line>Stop TB Department</addr-line>
,<institution>WHO</institution>
,<addr-line>Geneva</addr-line>
,<country>Switzerland</country>
.</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Reid, Alasdair" sort="Reid, Alasdair" uniqKey="Reid A" first="Alasdair" last="Reid">Alasdair Reid</name>
<affiliation><nlm:aff id="aff1"><addr-line>Stop TB Department</addr-line>
,<institution>WHO</institution>
,<addr-line>Geneva</addr-line>
,<country>Switzerland</country>
.</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Nathanson, Eva" sort="Nathanson, Eva" uniqKey="Nathanson E" first="Eva" last="Nathanson">Eva Nathanson</name>
<affiliation><nlm:aff id="aff1"><addr-line>Stop TB Department</addr-line>
,<institution>WHO</institution>
,<addr-line>Geneva</addr-line>
,<country>Switzerland</country>
.</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Pennas, Thad" sort="Pennas, Thad" uniqKey="Pennas T" first="Thad" last="Pennas">Thad Pennas</name>
<affiliation><nlm:aff id="aff1"><addr-line>Stop TB Department</addr-line>
,<institution>WHO</institution>
,<addr-line>Geneva</addr-line>
,<country>Switzerland</country>
.</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Fruth, Uli" sort="Fruth, Uli" uniqKey="Fruth U" first="Uli" last="Fruth">Uli Fruth</name>
<affiliation><nlm:aff id="aff2"><addr-line>Department of Immunization</addr-line>
,<addr-line>Vaccines and Biologicals</addr-line>
,<institution>WHO</institution>
,<addr-line>Geneva</addr-line>
,<country>Switzerland</country>
.</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Cunningham, Jane" sort="Cunningham, Jane" uniqKey="Cunningham J" first="Jane" last="Cunningham">Jane Cunningham</name>
<affiliation><nlm:aff id="aff3"><addr-line>Special Programme for Research and Training in Tropical Diseases</addr-line>
,<institution>WHO</institution>
,<addr-line>Geneva</addr-line>
,<country>Switzerland</country>
.</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Ignatius, Heather" sort="Ignatius, Heather" uniqKey="Ignatius H" first="Heather" last="Ignatius">Heather Ignatius</name>
<affiliation><nlm:aff id="aff4"><addr-line>Working Group on New Drugs</addr-line>
,<addr-line>Stop TB Partnership</addr-line>
,<addr-line>New York</addr-line>
,<addr-line>NY</addr-line>
,<country>USA</country>
.</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Raviglione, Mario C" sort="Raviglione, Mario C" uniqKey="Raviglione M" first="Mario C" last="Raviglione">Mario C. Raviglione</name>
<affiliation><nlm:aff id="aff1"><addr-line>Stop TB Department</addr-line>
,<institution>WHO</institution>
,<addr-line>Geneva</addr-line>
,<country>Switzerland</country>
.</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Koek, Irene" sort="Koek, Irene" uniqKey="Koek I" first="Irene" last="Koek">Irene Koek</name>
<affiliation><nlm:aff id="aff5"><addr-line>Infectious Diseases Division</addr-line>
,<addr-line>Bureau for Global Health</addr-line>
,<addr-line>US Agency for International Development</addr-line>
,<addr-line>1300</addr-line>
Pennsylvania Ave., Washington, DC 20523, USA.</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Espinal, Marcos" sort="Espinal, Marcos" uniqKey="Espinal M" first="Marcos" last="Espinal">Marcos Espinal</name>
<affiliation><nlm:aff id="aff6"><addr-line>Stop TB Partnership Secretariat</addr-line>
,<institution>WHO</institution>
,<addr-line>Geneva</addr-line>
,<country>Switzerland</country>
.</nlm:aff>
</affiliation>
</author>
</analytic>
<series><title level="j">Bulletin of the World Health Organization</title>
<idno type="ISSN">0042-9686</idno>
<imprint><date when="2007">2007</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><title>Abstract</title>
<p>The Global Plan to Stop TB 2006–2015 is a road map for policy-makers and managers of national programmes. It sets out the key actions needed to achieve the targets of the Millennium Development Goals relating to tuberculosis (TB): to halve the prevalence and deaths by 2015 relative to 1990 levels and to save 14 million lives. Developed by a broad coalition of partners, the plan presents a model approach combining interventions that can feasibly be supplied on the ground. The main areas of activity set out in the plan are: scaling up interventions to control tuberculosis; promoting the research and development of improved diagnostics, drugs and vaccines; and engaging in related activities for advocacy, communications and social mobilization.</p>
<p>Scenarios for the planning process were developed; these looked at issues both globally and in seven epidemiological regions. The scenarios made ambitious but realistic assumptions about the pace of scale-up and implementation coverage of the activities. A mathematical model was used to estimate the impact of scaling up current interventions based on data from studies of tuberculosis biology and from experience with tuberculosis control in diverse settings.</p>
<p>The estimated costs of the activities set out in the Global Plan were based on implementing interventions and researching and developing drugs, diagnostics and vaccines; these costs were US$ 56 billion over 10 years. When translated into cost per disability adjusted life year averted, these costs compare favourably with those of other public health interventions. This approach to planning for global tuberculosis control is a valuable example of developing plans to improve global health that has relevance for other health issues.</p>
</div>
</front>
</TEI>
<pmc article-type="other" xml:lang="EN"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Bull World Health Organ</journal-id>
<journal-id journal-id-type="publisher-id">BLT</journal-id>
<journal-title>Bulletin of the World Health Organization</journal-title>
<issn pub-type="ppub">0042-9686</issn>
<publisher><publisher-name>World Health Organization</publisher-name>
</publisher>
</journal-meta>
<article-meta><article-id pub-id-type="pmid">17639217</article-id>
<article-id pub-id-type="pmc">2636650</article-id>
<article-id pub-id-type="publisher-id">06-037820</article-id>
<article-id pub-id-type="doi">10.2471/06.037820</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Policy and Practice</subject>
</subj-group>
</article-categories>
<title-group><article-title>Planning to improve global health: the next decade of tuberculosis control</article-title>
<trans-title xml:lang="FR">Amélioration de la santé dans le monde : planification des activités de lutte antituberculeuse pour la prochaine décennie</trans-title>
<trans-title xml:lang="ES">Planificar las mejoras de la salud mundial: la lucha antituberculosa en la próxima década</trans-title>
<trans-title xml:lang="AR">التخطيط لتحسين الصحة في العالم: العقد القادم لمكافحة السل</trans-title>
</title-group>
<contrib-group><contrib contrib-type="author"><name><surname>Maher</surname>
<given-names>Dermot</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>a</sup>
</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Dye</surname>
<given-names>Chris</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>a</sup>
</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Floyd</surname>
<given-names>Katherine</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>a</sup>
</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Pantoja</surname>
<given-names>Andrea</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>a</sup>
</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Lonnroth</surname>
<given-names>Knut</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>a</sup>
</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Reid</surname>
<given-names>Alasdair</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>a</sup>
</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Nathanson</surname>
<given-names>Eva</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>a</sup>
</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Pennas</surname>
<given-names>Thad</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>a</sup>
</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Fruth</surname>
<given-names>Uli</given-names>
</name>
<xref ref-type="aff" rid="aff2"><sup>b</sup>
</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Cunningham</surname>
<given-names>Jane</given-names>
</name>
<xref ref-type="aff" rid="aff3"><sup>c</sup>
</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Ignatius</surname>
<given-names>Heather</given-names>
</name>
<xref ref-type="aff" rid="aff4"><sup>d</sup>
</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Raviglione</surname>
<given-names>Mario C</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>a</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes"><name><surname>Koek</surname>
<given-names>Irene</given-names>
</name>
<xref ref-type="aff" rid="aff5"><sup>e</sup>
</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Espinal</surname>
<given-names>Marcos</given-names>
</name>
<xref ref-type="aff" rid="aff6"><sup>f</sup>
</xref>
</contrib>
<aff id="aff1"><label>a</label>
<addr-line>Stop TB Department</addr-line>
,<institution>WHO</institution>
,<addr-line>Geneva</addr-line>
,<country>Switzerland</country>
.</aff>
<aff id="aff2"><label>b</label>
<addr-line>Department of Immunization</addr-line>
,<addr-line>Vaccines and Biologicals</addr-line>
,<institution>WHO</institution>
,<addr-line>Geneva</addr-line>
,<country>Switzerland</country>
.</aff>
<aff id="aff3"><label>c</label>
<addr-line>Special Programme for Research and Training in Tropical Diseases</addr-line>
,<institution>WHO</institution>
,<addr-line>Geneva</addr-line>
,<country>Switzerland</country>
.</aff>
<aff id="aff4"><label>d</label>
<addr-line>Working Group on New Drugs</addr-line>
,<addr-line>Stop TB Partnership</addr-line>
,<addr-line>New York</addr-line>
,<addr-line>NY</addr-line>
,<country>USA</country>
.</aff>
<aff id="aff5"><label>e</label>
<addr-line>Infectious Diseases Division</addr-line>
,<addr-line>Bureau for Global Health</addr-line>
,<addr-line>US Agency for International Development</addr-line>
,<addr-line>1300</addr-line>
Pennsylvania Ave., Washington, DC 20523, USA.</aff>
<aff id="aff6"><label>f</label>
<addr-line>Stop TB Partnership Secretariat</addr-line>
,<institution>WHO</institution>
,<addr-line>Geneva</addr-line>
,<country>Switzerland</country>
.</aff>
</contrib-group>
<author-notes><corresp id="cor1">Correspondence to Irene Koek (e-mail: <email xlink:href="ikoek@usaid.gov">ikoek@usaid.gov</email>
).</corresp>
</author-notes>
<pub-date pub-type="ppub"><month>5</month>
<year>2007</year>
</pub-date>
<volume>85</volume>
<issue>5</issue>
<fpage>341</fpage>
<lpage>347</lpage>
<history><date date-type="received"><day>19</day>
<month>10</month>
<year>2006</year>
</date>
<date date-type="rev-recd"><day>29</day>
<month>1</month>
<year>2007</year>
</date>
<date date-type="accepted"><day>12</day>
<month>2</month>
<year>2007</year>
</date>
</history>
<permissions><copyright-statement>© World Health Organization (WHO) 2007. All rights reserved.</copyright-statement>
<copyright-year>2007</copyright-year>
</permissions>
<abstract><title>Abstract</title>
<p>The Global Plan to Stop TB 2006–2015 is a road map for policy-makers and managers of national programmes. It sets out the key actions needed to achieve the targets of the Millennium Development Goals relating to tuberculosis (TB): to halve the prevalence and deaths by 2015 relative to 1990 levels and to save 14 million lives. Developed by a broad coalition of partners, the plan presents a model approach combining interventions that can feasibly be supplied on the ground. The main areas of activity set out in the plan are: scaling up interventions to control tuberculosis; promoting the research and development of improved diagnostics, drugs and vaccines; and engaging in related activities for advocacy, communications and social mobilization.</p>
<p>Scenarios for the planning process were developed; these looked at issues both globally and in seven epidemiological regions. The scenarios made ambitious but realistic assumptions about the pace of scale-up and implementation coverage of the activities. A mathematical model was used to estimate the impact of scaling up current interventions based on data from studies of tuberculosis biology and from experience with tuberculosis control in diverse settings.</p>
<p>The estimated costs of the activities set out in the Global Plan were based on implementing interventions and researching and developing drugs, diagnostics and vaccines; these costs were US$ 56 billion over 10 years. When translated into cost per disability adjusted life year averted, these costs compare favourably with those of other public health interventions. This approach to planning for global tuberculosis control is a valuable example of developing plans to improve global health that has relevance for other health issues.</p>
</abstract>
<trans-abstract xml:lang="FR"><title>Résumé</title>
<p>Le plan mondial Halte à la tuberculose 2006-2015 fournit des lignes directrices aux décideurs politiques et aux directeurs de programmes nationaux. Il présente les interventions clés nécessaires à la réalisation des objectifs du Millénaire pour le développement concernant la tuberculose (TB), à savoir faire baisser de moitié, entre 1990 et 2015, la prévalence de cette maladie et la mortalité lui étant imputable et épargner 14 millions de vies. Mis au point par un vaste groupement de partenaires, le plan propose un modèle de stratégie associant des interventions faciles à mettre en œuvre sur le terrain. Les principaux domaines d’activité prévus sont : le passage à l’échelle supérieure des interventions de lutte antituberculeuse, la promotion des travaux de recherche et développement concernant des outils diagnostiques, des médicaments et des vaccins plus performants et l’engagement dans des activités connexes de plaidoyer, de communication et de mobilisation sociale.</p>
<p>Des scénarios ont été développés pour aider au processus de planification : ils considèrent les problèmes à l’échelle mondiale et dans sept régions épidémiologiques. Ces scénarios reposent sur des hypothèses ambitieuses, mais réalistes, quant au rythme de passage à l’échelle supérieure et de développement de la couverture des activités. Un modèle mathématique a été utilisé pour évaluer l’impact du passage à l’échelle supérieure des interventions en cours à partir de données d’études biologiques sur la tuberculose et de l’expérience acquise dans divers contextes en matière de lutte antituberculeuse.</p>
<p>Les estimations de coûts pour les activités prévues par le Plan mondial correspondent à la mise en œuvre des interventions et aux travaux de recherche et développement de médicaments, d’outils diagnostiques et de vaccins améliorés ; elles se montent à US$ 56 milliard sur 10 ans. Une fois convertis en coûts par année de vie corrigée de l’incapacité (DALY), ces chiffres supportent favorablement la comparaison avec ceux d’autres interventions de santé publique. Cette stratégie de planification de la lutte contre la tuberculose au niveau mondial est un exemple utile de programme de développement pour l’amélioration de la santé dans le monde, qui intéresse d’autres problèmes sanitaires.</p>
</trans-abstract>
<trans-abstract xml:lang="ES"><title>Resumen</title>
<p>El Plan Mundial para Detener la Tuberculosis 2006-2015 es una hoja de ruta para instancias normativas y gestores de programas nacionales. En él se establecen las principales intervenciones necesarias para alcanzar las metas de los Objetivos de Desarrollo del Milenio relacionadas con la tuberculosis: reducir a la mitad la prevalencia de esta enfermedad y la mortalidad por esa causa para 2015 en comparación con los niveles de 1990 y salvar así 14 millones de vidas. Elaborado por una amplia coalición de asociados, el plan presenta un modelo que combina diversas intervenciones que pueden aplicarse de forma viable sobre el terreno. Las áreas principales de actividad contempladas en el plan son las siguientes: expansión de las intervenciones de lucha antituberculosa; promoción de la investigación y el desarrollo de mejores medios diagnósticos, medicamentos y vacunas; y participación en las actividades relacionadas con la promoción, las comunicaciones y la movilización social.</p>
<p>Se desarrollaron distintos escenarios para el proceso de planificación, considerando los problemas a nivel mundial y en siete regiones epidemiológicas. Los escenarios partían de hipótesis ambiciosas pero realistas sobre el ritmo de expansión y la cobertura de aplicación de las actividades. Se utilizó un modelo matemático para estimar la repercusión de la expansión de las intervenciones actuales sobre la base de datos procedentes de estudios de la biología de la tuberculosis y de la experiencia de la lucha antituberculosa en diversos entornos.</p>
<p>Los costos estimados de las actividades establecidas en el Plan Mundial -correspondientes a la ejecución de las intervenciones y la investigación y el desarrollo de medicamentos, medios de diagnóstico y vacunas- ascendían a US$ 56 000 millones a lo largo de 10 años. Traducidos al costo por AVAD (años de vida ajustados en función de la discapacidad) evitado, la cifra es más baja que la de otras intervenciones de salud pública. Este método de planificación del control mundial de la tuberculosis brinda un valioso ejemplo para elaborar planes de mejora de la salud mundial que revistan interés para otros problemas sanitarios.</p>
</trans-abstract>
<trans-abstract xml:lang="AR"><title>ملخص</title>
<p>تُعد الخطة العالمية لدحر السل 2006 – 2015 بمثابة خارطة طريق لأصحاب القرار السياسي ومديري البرامج الوطنية؛ فەي توطِّد الأنشطة الرئيسية اللازمة لتحقيق المرامي الإنمائية للألفية وأەدافەا المتعلِّقة بالسل؛ وەي الوصول بمعدلات الانتشار والوفيات عام 2015 إلى نصف ما كانت عليە عام 1990، وإنقاذ حياة 14 مليون نسمة. وتمثـِّل الخطة العالمية التي شارك في إعدادەا تحالف واسع النطاق من الشركاء أسلوباً نموذجياً يضم التدخلات التي يمكن تنفيذەا بسەولة في الواقع. أما مجالات العمل الرئيسية التي وطَّدتەا الخطة العالمية لدحر السل 2006 – 2015 فەي: النەوض بالتدخلات لمكافحة السل، وتعزيز البحوث وابتكار مواد تشخيصية وأدوات ولقاحات مُحَسَّنة، والمساەمة في الأنشطة المتعلِّقة بالحملات الإعلامية وبأنشطة التواصل، واستنەاض المجتمع لمكافحة السل.</p>
<p>وقد أُعِدَّت السيناريوەات لعملية التخطيط، وتـتناول ەذە السيناريوەات القضايا على الصعيد العالمي وعلى صعيد الأقاليم الإبيديميولوجية السبعة. وقد وَضَعَتْ السيناريوەات افتـراضاتٍ طموحةً ولكنەا واقعية حول سرعة النەوض بالأنشطة وحول التغطية بتنفيذەا، كما استُخْدِم نموذج حسابي لتقدير أثر النەوض بالتدخلات الحالية اعتماداً على المعطيات التي جُمِعَتْ من دراسات حول بيولوجيا السل ومن الخبرات حول مكافحة السل في مواقع واسعة التباين.</p>
<p>وقد ارتكزت التكاليف المقدَّرة للأنشطة التي وضعتەا الخطة العالمية لدحر السل 2006 – 2015، على تنفيذ التدخلات وعلى البحوث وعلى ابتكار الأدوية والمواد التشخيصية واللقاحات، وقُدِّرَتْ ەذە التكاليف بـ 56 مليون دولار على مدى عشر سنوات، أما عند تـرجمتەا إلى التكاليف وفق سنوات العمر المصحِّحة باحتساب مُدَد العجز التي يمكن تفاديەا، فإن ەذە التكاليف تفوق التدخلات الأخرى للصحة العمومية عند مقارنتەا بەا. إن ەذا الأسلوب من التخطيط لمكافحة السل على الصعيد العالمي يُعد مثالاً ەاماً لإعداد الخطط لتحسين الصحة في العالم والتي قد يكون لەا علاقة مع القضايا الصحية الأخرى.</p>
</trans-abstract>
</article-meta>
</front>
</pmc>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaSubSaharaV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E71 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000E71 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= SidaSubSaharaV1 |flux= Pmc |étape= Corpus |type= RBID |clé= |texte= }}
![]() | This area was generated with Dilib version V0.6.32. | ![]() |